Company Overview


ZYUS is inspired by science. Born from the abstraction of ‘science’ and ‘zygote’ (the fusion of two cells), we represent the beginning of life and the importance of improving quality of life. We believe in taking a forward, collaborative approach and place high value in our teamwork, partnerships and commitment to the broader ‘us' - society. We believe that together, we can bring phyto-therapeutics to the global medical market.

About ZYUS Life Sciences

ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value.

ZYUS’ unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients’ lives.

Zyus office entrance

Our Approach

ZYUS is primarily focused on the development, patent protection and regulatory approval of its drug product candidates through clinical trials. Simultaneously, ZYUS is committed to offering patients immediate access to its foundational products for compassionate reasons.

Pharmaceutical Drug Product Candidates

The development, protection, and regulatory approval of our pharmaceutical drug product candidates from authorities such as the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Health Canada. Followed by commercialization of these proprietary drug products for use in treatment of specific diseases and indications.

Access to Foundational Products

While the primary focus is on the clinical development of ZYUS' regulatory approved pharmaceutical drug product candidates, we also are engaged in the commercialization of our exempt market therapeutics such as cannabinoid oils, softgel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.

Brent Zettl, ZYUS President & CEO

Brent Zettl, ZYUS President & CEO

Prior to becoming the President and CEO of ZYUS, Mr. Zettl was the co-founder of Prairie Plant Systems Inc. in 1988 (“PPS”), CanniMed Ltd. in 2013 and their parent company, CanniMed Therapeutics Inc., in 2016. PPS and CanniMed Ltd. became the first two licensed producers of cannabis under the Marihuana for Medical Purposes Regulations and were the exclusive suppliers of medical cannabis to Health Canada from 2000 to 2014. In March 2018, CanniMed Therapeutics Inc. was acquired by Aurora Cannabis Inc. for approximately CAD$1.2 billion, the largest acquisition of a cannabis company at the time.

With over 20 years of experience pioneering the medical cannabis industry, ZYUS has a vision to reimagine the potential of cannabinoids - in pursuit of transformational impact on patients' lives.